- Overview
- 150 Years
- News
- Biographies
- Speeches
- Photos
- TV Footage
- Publications
- Video Center
- Social Media Channels
- Apps
- Events
- Stories
- Media Contact
News
SPECIALIZED PRESS
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan more
Thursday - May 16, 2013
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands more
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands more
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival more
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival more
Wednesday - May 15, 2013Growing weed resistance drives demand for alternative technologies:
Bayer CropScience announces intention to construct a state-of-the-art facility for glufosinate-ammonium herbicide more
Wednesday - May 15, 2013Dr. Herbert Heitmann to be new Head of Communications and Government Relations at Bayer more
SPECIALIZED PRESS
Not intended for U.S. and UK Media
Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer more
Tuesday - May 14, 2013Bayer Head of Communications will join soccer team
Michael Schade will become Managing Director of Bayer 04 Leverkusen more
Publications
Events
Wednesday, July 31, 2013
Q2 2013 Interim Report
Additional Press Events
Investor Relations Events
BayKomm Events
Q2 2013 Interim Report
